Full Picture

Extension usage examples:

Here's how our browser extension sees the article:
Appears moderately imbalanced

Article summary:

1. PD-1/PD-L1 antibody drugs have achieved great success in the treatment of advanced malignant tumors, and have been approved by FDA for clinical application.

2. The PD-1/PD-L1 signaling pathway plays an important role in tumor immune escape, and the combination of PD-L1 and PD-1 can induce T cell apoptosis, incapacity, and exhaustion.

3. Tumor immunotherapy mainly refers to anti-CTLA-4 treatment and anti-PD-1/PD-L1 treatment, with six PD-1/PD-L1 inhibitors that have been marketed worldwide for various indications such as non-small cell lung cancer, malignant melanoma, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, liver cancer, classical Hodgkin's lymphoma, Merkel cell carcinoma and bladder cancer.

Article analysis:


1. 偏袒PD-1/PD-L1抗体药物


2. 缺乏对其他肿瘤免疫治疗方法的介绍


3. 缺乏对PD-1/PD-L1机制的全面解释


4. 缺乏对临床试验结果的详细分析


5. 缺乏对反驳观点的探讨